Company Overview and News

1
Southcross Energy Partners, L.P. Announces James W. Swent III Elected as Chairman, President and Chief Executive Officer

2018-09-18 globenewswire
DALLAS, Texas, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Southcross Energy Partners, L.P. (NYSE: SXE) (“Southcross” or the “Partnership”) announced today that James (“Jay”) W. Swent III has been elected Chairman, President and Chief Executive Officer by its Board of Directors. David W. Biegler, who has served as interim Chairman, President and Chief Executive Officer since March 2018, will remain a director.
PGNPQ SXE

1
Southcross Energy Partners, L.P. Receives NYSE Continued Listing Standard Letter

2018-08-31 globenewswire
DALLAS, Texas, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Southcross Energy Partners, L.P. (NYSE: SXE) (“Southcross” or the “Partnership”) was notified on August 27, 2018 by the New York Stock Exchange ("NYSE") that the Partnership does not presently satisfy the NYSE's continued listing standard requiring the average closing price of the Partnership's common units to be at least $1.00 per common unit over a period of 30 consecutive trading days.
DTK SXE

1
Southcross Energy Partners (SXE) CEO David Biegler on Q2 2018 Results - Earnings Call Transcript

2018-08-20 seekingalpha
Good morning and welcome to Southcross Energy Partners Update Call. As a reminder, today’s call is being recorded and your participation implies consent to such recording. At this time, all participants are in listen-only mode. The question-and-answer session will follow the formal presentation.
DTK SXE

1
American Midstream: Attitude Adjustment

2018-08-19 seekingalpha
The sale of a division decreased the debt to EBITDA ratio to 4.8. More decreases from sales are likely.
SXE

2
A Well Covered 7.1% Yield From A Deeply Hated Growth Stock

2018-08-15 seekingalpha
Few market sectors are as despised as the midstream sector. The ETRACS 2xMonthly Leveraged Alerian MLP Infrastructure Index ETN Series B (MLPQ) bottomed at $25.63 on 3/27/2018. Despite the historic bull market, this was a 2 year drop of about 50%. Midstream has suffered despite soaring U.S. oil and natural gas production which should favor pipelines and other infrastructure required to process and transport it.
AMID KMI EPD SXE KMR KMRFZ CVB

1
SXE / Southcross Energy Partners, L.P. 10-Q (Quarterly Report)

2018-08-14 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SXE

2
Southcross Energy Partners, L.P. Reports Second Quarter Results

2018-08-14 globenewswire - 1
DALLAS, Texas, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Southcross Energy Partners, L.P. (NYSE: SXE) (“Southcross” or the “Partnership”) today announced second quarter financial and operating results.
AMID SXE

2
American Midstream: Despite Some Negative Recent Headlines, Results Are Decent

2018-08-11 seekingalpha - 1
The company saw strong YOY revenue growth due largely to higher throughput as oil and gas drilling activity picks up.
AMID SXE

1
SXE / Southcross Energy Partners, L.P. / Southcross Holdings GP, LLC - SC 13D/A (Activist Investment)

2018-08-09 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SXE

1
SXE / Southcross Energy Partners, L.P. / Southcross Holdings GP, LLC - SC 13D/A (Activist Investment)

2018-08-09 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SXE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 84130C100